Safety
GLP-1 side effects: common symptoms and serious warning signs
GLP-1 treatments often cause gastrointestinal symptoms, but the safety plan must distinguish common effects from symptoms requiring urgent assessment.
Common digestive effects
Nausea, vomiting, diarrhea, constipation, and abdominal symptoms appear in the labels of several GLP-1 medicines. Their frequency varies by product, dose, study, and population. A number from one trial should not be presented as the rate for every drug or compounded preparation.
Symptoms can be more noticeable during escalation. Tell the clinician when they interfere with eating, drinking, sleep, or daily activities. Ask about tolerability before increasing a dose, and do not interpret discomfort as proof that a treatment is working better.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information
Warning signs need assessment
Severe persistent abdominal pain, especially with vomiting, may require evaluation for pancreatitis or other serious disease. Symptoms of a severe allergic reaction, inability to maintain fluid intake, or significant dehydration warrant prompt medical care.
Vomiting and diarrhea can contribute to kidney injury through fluid loss. A clinic should provide a clear route to clinical assessment rather than treating every symptom as a customer-service question. Use emergency services for severe allergic symptoms or other emergencies.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information
Low blood sugar and medicine combinations
Glucose-dependent effects do not eliminate hypoglycemia risk. Insulin or sulfonylureas used alongside these treatments can increase that risk, and the prescriber may adjust them. Do not independently change diabetes medicines based on one reading.
Ask what symptoms and glucose results should trigger the clinician's hypoglycemia plan. If you have eye disease related to diabetes, discuss monitoring, particularly when glucose control changes quickly.
Sources: Ozempic prescribing information · Mounjaro prescribing information
A usable follow-up plan
Keep the product, formulation, dose, escalation date, symptom pattern, and medicine list available. Ask who handles urgent symptoms, when follow-up is scheduled, and what to do if treatment is interrupted.
Tell the anesthesia team about treatment before planned surgery or sedation. Review pregnancy plans and product-specific contraception precautions. Compounded treatment requires its own formulation assessment and does not inherit approved-product safety evidence.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information · Foundayo prescribing information · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.